Interleukin-10 antibodies
View Patent ↗The methods and compositions provided herein relate generally to IL-10 specific antibodies and uses thereof. More specifically, the methods and compositions provided herein relate to humanized IL-10 specific antibodies and methods to use such antibodies in modulating the biological activity of IL-10, particularly in autoimmune disorders and pathogen-mediated immunopathology.
1. A humanized recombinant antibody or an antigen binding fragment thereof, both of which bind to IL-10, comprising:
a) at least one antibody light chain variable region, wherein said light chain variable region is SEQ ID NO: 4; and
b) at least one antibody heavy chain variable region, wherein said heavy chain variable region is SEQ ID NO: 9.
2. The antibody of claim 1 , further comprising a heavy chain constant region, wherein the heavy chain constant region comprises a γ1, γ2, γ3,or γ4 human heavy chain constant region or a variant of the human heavy chain constant region.
3. The antibody of claim 1 , further comprising a light chain constant region, wherein the light chain constant region comprises a lambda or a kappa human light chain constant region.
4. The antibody of claim 1 , wherein the binding fragment is selected from group consisting of Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′) 2, and a diabody.
5. The antibody of claim 1 , wherein the antibody, or antigen binding fragment thereof, comprises the polypeptide sequence of SEQ ID NO: 5.
6. The antibody of claim 1 , wherein the antibody , or antigen binding fragment thereof, comprises the polypeptide sequence of SEQ ID NO: 10.
7. A composition comprising an antibody or an antigen binding fragment thereof, in combination with a pharmaceutically acceptable carrier or diluent, wherein the antibody is the antibody of claim 1 .
8. The composition of claim 7 , further comprising an immunosuppressive agent.
9. A method of treating systemic lupus erythematosus in a human subject comprising administering to a subject in need thereof, an effective amount of the antibody or antigen binding fragment of claim 1 .
10. A method of treating lupus nephritis in a human subject comprising administering to a subject in need thereof, an effective amount of the antibody or antigen binding fragment of claim 1 .